Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13593209 | 0.81 | ALDH1A1 (0.46) | KDM4ETDP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1460245 | 0.79 | RECQL (0.42) | RECQLKDM4EALDH1A1PDE2AHTT | |
| SCHEMBL29664640 | 0.77 | LOXL2 (0.61) | LOXLOXL2CLK1DYRK1APIK3CD | |
| SCHEMBL23215147 | 0.77 | LOXL2 (0.61) | LOXLOXL2CLK1DYRK1APIK3CD | |
| SCHEMBL1046247 | 0.74 | ALDH1A1 (0.50) | KDM4ETDP1ALDH1A1FLT3PKM | |
| SCHEMBL9203057 | 0.74 | ALDH1A1 (0.43) | KDM4ETDP1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL15700314 | 0.73 | TPMT (0.37) | KDM4ETDP1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL10180543 | 0.73 | RECQL (0.38) | RECQLKDM4EALDH1A1PDE2AHTT | |
| SCHEMBL5596892 | 0.73 | LMNA (0.42) | RECQLTDP1ALDH1A1PDE2ACLK1 | |
| SCHEMBL17469030 | 0.73 | ALDH1A1 (0.48) | RECQLKDM4ETDP1ALDH1A1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816368-B2 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2010-10-19 | — | — | US | disclosed |
| US-20090042924-A1 | Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | disclosed |
| US-7456193-B2 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2008-11-25 | — | — | US | disclosed |
| EP-1556380-B1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2006-04-12 | — | — | EP | disclosed |
| US-20050222192-A1 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | SANOFI-AVENTIS (FR) | 2005-10-06 | — | — | US | disclosed |
| EP-1556380-A1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037821-A1 | PYRIDOINDOLONE DERIVATIVES SUBSTITUTED IN THE 3-POSITION BY A HETEROCYCLIC GROUP, PREPARATION THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222192-A1 | Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics | CBR3, PNPO, CBR1 | RECQL 1219/4885KDM4E 2222/4885TDP1 2129/4885 |
| US-20090042924-A1 | Pyridoindolone Derivatives Substituted in the 3-position by a Heterocyclic Group, Their Preparation and Their Application in Therapeutics | PNPO, DPYD, PDXK | RECQL 75/4885KDM4E 2743/4885TDP1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.